Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Clinical evidence RECONNECT trials: The FDA approval was based on two Phase 3 trials involving over 1,200 premenopausal women with HSDD: Significant increases in Female Sexual Function Index-desire domain scores Reduced distress related to low sexual desire Benefits maintained through 52-week open-label extension Rapid improvement when placebo patients switched to active treatment Earlier research: A 2006 study in premenopausal women with sexual arousal disorder found significantly more women reported moderate or high sexual desire after PT-141 compared to placebo (p=0.0114)
Pair with Vitamin C: This is the essential link for both glutathione and collagen
It does something more concrete and more consequential: it sets a clearer federal lane for licensed compounding pharmacies to prepare the substance under prescription and reduces use of research use only suppliers that have no clinical quality obligations (National Law Review)
# Impact on Primary Pain Outcomes: The study found that both 20 g/day of inulin and digital PSE (delivered via the Joint Academy platform) significantly reduced pain compared to a placebo (maltodextrin)
US$ 20.47
US$ 20.52
US$ 27.43
US$ 21.31
US$ 28.12
US$ 25.66
US$ 28.94
US$ 29.21
US$ 29.70
US$ 24.44
US$ 24.49
